Biomarck Pharmaceuticals, Ltd. is a clinical stage biotechnology company focused on treating patients with inflammatory and immunological diseases, using our platform of patent-protected peptides that have been developed to inhibit MARCKS. As a critical component of the inflammatory process, MARCKS is responsible for neutrophil aggregation at the site of inflammation and cytokine release. Inhibiting MARCKS with our peptides reduces the adverse effects of inflammation, including acute respiratory distress syndrome (ARDS) and cytokine storm. Phase 2 trials have been completed with our lead peptide, BIO-11006, in ARDS, chronic obstructive pulmonary disease (COPD), and non-small cell lung cancer (NSCLC), supporting safety and efficacy in these three potential indications. In oncology, inhibiting MARCKS with our peptides blocks migration of NSCLC cells in vitro and inhibits metastasis in animal models of NSCLC.
Biomarck has developed a portfolio of novel peptides to inhibit MARCKS, a critical component of the inflammatory process.
Phase 2 trials have been completed with Biomarck’s lead peptide, BIO-11006, in ARDS, COPD, and NSCLC, with promising safety and efficacy data.